시장보고서

상품코드

1584133

간암 치료제 시장 : 약제 클래스별, 치료 유형별, 투여 경로별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Liver Cancer Drug Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 260 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

간암 치료제 시장 규모는 2023년에 31억 5,190만 달러에 달하며, 2024-2032년 17.82%의 CAGR로 확대

간암 치료제 시장 - 시장 역학

간암 이환율의 상승이 간암 치료제 시장의 성장을 촉진

세계보건기구(WHO)의 보고에 따르면 지난 20년간 간암 발병률이 75% 이상 증가했다고 합니다. 미국 암 협회는 2023년까지 미국에서만 약 43,000명의 간암 환자가 새로 진단될 것으로 추정하고 있으며, 이는 주로 B형 및 C형 간염 감염률 증가, 과도한 알코올 섭취, 비만 등이 원인으로 꼽힙니다. 조기 발견과 조기 치료의 중요성에 대한 인식이 높아짐에 따라 제약사들은 혁신적인 치료법을 개발하며 대응하고 있습니다. 예를 들어 면역관문억제제와 같은 표적 치료제의 최근 발전은 진행성 간암 환자의 생존율을 개선하는 데 유망한 것으로 나타났습니다. 또한 미국 간학회와 같은 조직은 치료 옵션을 늘리고 이 질병을 더 잘 이해하기 위한 연구와 임상시험을 추진하여 빠르게 발전하는 이 시장에서 효과적인 치료법에 대한 긴급한 필요성에 대응하고 있습니다.

간암 치료제 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032) 동안 연평균 약 17.82%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

약물 유형별로는 VEGF 억제제가 22023년 가장 높은 시장 점유율을 차지했습니다.

치료 유형별로는 2023년 표적치료제가 주요 치료 유형으로 부상할 것으로 예상됩니다.

투여 경로별로는 경구제가 2023년 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 매출을 주도했습니다.

간암 치료제 시장 - 세분화 분석 :

간암 치료제 세계 시장은 약물 유형별, 치료 유형별, 투여 경로별, 최종사용자별, 지역별 시장으로 구분됩니다.

약물 유형에 따라 VEGF 억제제, PD-1/PD-L1 억제제, 티로신 키나아제 억제제, 면역관문억제제 등 4가지로 분류되며, VEGF 억제제는 간세포암에 대한 효능이 입증되어 간암 치료제 시장에서 가장 높은 순위를 차지하고 있으며, PD-1/PD- L1 억제제가 그 뒤를 이어 유망한 면역치료 옵션을 제공합니다. 그 다음으로는 티로신 키나아제 억제제(TKI), 면역관문억제제가 진행성 환자에서 선호되고 있습니다.

시장은 치료법 유형에 따라 화학요법, 표적치료제, 면역요법, 병용요법 등 4가지 범주로 나뉩니다. 표적치료제는 높은 치료 효과와 정확성으로 간암 치료제 시장을 선도하고 있습니다. 면역요법은 진행성 간암에 대한 혁신적인 치료 옵션을 제공하며 근소한 차이로 그 뒤를 이었습니다. 그 다음으로는 병용요법이 뒤를 이었지만, 화학요법은 여전히 전통적인 접근법으로 진행성 간암에 대한 효과가 제한적이라는 평가를 받고 있습니다.

간암 치료제 시장 - 지역적 인사이트

북미가 간암 치료제 시장을 주도하고 있습니다. 특히 미국 식품의약국(FDA)은 2022년 렌바티닙과 펨브롤리주맙을 포함한 새로운 병용요법을 승인하여 진행성 간세포암(HCC) 환자의 치료 옵션을 크게 향상시켰으며, 간암 발병률이 꾸준히 증가하고 있다고 보고했습니다. 또한 미국 암학회는 간암 발병률이 꾸준히 증가하고 있다고 보고하고, 더 나은 진단 툴와 치료 옵션을 위한 연구 구상에 대한 자금 지원을 늘렸습니다. 유럽에서는 독일과 프랑스와 같은 국가에서 혁신적인 약물 조합에 초점을 맞춘 임상시험이 급증하고 있으며, 이는 환자 치료 강화에 대한 노력을 반영하고 있습니다. 아시아태평양은 간염과 관련된 간암의 높은 유병률로 인해 간암 연구에 많은 투자가 이루어지고 있으며, 중요한 지역으로 부상하고 있습니다. 일본의 제약회사와 연구기관의 제휴와 같은 공동연구는 새로운 치료법 개발을 촉진하는 것을 목표로 하고 있으며, 간암과 효과적으로 싸우기 위한 전 세계의 노력을 강조하고 있습니다.

간암 치료제 시장 - 경쟁상황:

간암 치료제 시장 경쟁 구도는 주로 북미가 주도하고 있으며, 바이엘, 브리스톨-마이어스 스퀴브, 머크 등 주요 제약사들이 적극적으로 포트폴리오를 확장하고 있습니다. 치료 성적 개선을 목표로 하는 새로운 솔라페닙 제제를 출시할 예정이라고 발표했습니다. 한편, 브리스톨 마이어스 스퀴브는 미국 국립암연구소와의 공동연구를 통해 새로운 면역요법 개발을 가속화하여 환자들의 치료 옵션을 크게 확대했습니다. 최근 머크는 간암 연구 전문 생명공학 기업을 인수하여 시장 입지를 강화하고 혁신적인 치료법 파이프라인을 확장했습니다. 또한 유럽 시장에서는 맞춤형 의료에 대한 관심이 높아짐에 따라 기존 약물과 신약을 결합한 병용요법 임상시험이 활발히 진행되고 있습니다. 이러한 움직임은 간암 치료 옵션을 넓히고 환자의 예후를 개선하기 위해서는 공동 연구, 혁신, 전략적 제휴가 필수적이라는 역동적인 경쟁 환경을 강조하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 간암 치료제 업계

경쟁 대시보드
기업 개요
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Genentech, Inc.(Roche)
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck &Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Others

제13장 애널리스트의 전방위 전망

KSA 24.11.14

REPORT HIGHLIGHT

Liver Cancer Drug Market size was valued at USD 3,151.90 Million in 2023, expanding at a CAGR of 17.82% from 2024 to 2032.

The Liver Cancer Drug Market focuses on pharmaceutical treatments for hepatocellular carcinoma (HCC), the most common type of liver cancer, accounting for approximately 75% of all liver cancer cases. Rising incidences of liver cancer, attributed to factors like hepatitis infection and alcohol consumption, have heightened the demand for effective therapies. For instance, the World Health Organization estimates that liver cancer caused around 830,000 deaths globally in 2020. The advent of targeted therapies, such as sorafenib and lenvatinib, has transformed treatment protocols, offering new hope for patients. However, challenges persist, including the high cost of innovative treatments and limited access to care in low-resource settings, which can hinder market growth. Furthermore, the lack of early diagnostic tools often results in late-stage diagnosis, complicating treatment options. Nevertheless, opportunities abound in research for novel therapies, particularly immunotherapy and combination treatments, as well as initiatives aimed at increasing awareness and screening, which could lead to earlier diagnosis and better patient outcomes in the liver cancer landscape.

Liver Cancer Drug Market- Market Dynamics

Rising Incidences of Liver Cancer Drive Growth in the Liver Cancer Drug Market

The rising incidences of liver cancer are significantly driving growth in the Liver Cancer Drug Market, as reported by the World Health Organization, which indicates that liver cancer cases have increased by over 75% in the past two decades. This alarming trend is primarily attributed to rising rates of hepatitis B and C infections, excessive alcohol consumption, and obesity, with the American Cancer Society estimating that in 2023, approximately 43,000 new cases of liver cancer will be diagnosed in the U.S. alone. As awareness grows regarding the importance of early detection and treatment, pharmaceutical companies are responding by developing innovative therapies. For instance, recent advancements in targeted therapies, such as immune checkpoint inhibitors, have shown promise in improving survival rates for patients with advanced liver cancer. Additionally, organizations like the American Association for the Study of Liver Diseases are promoting research and clinical trials to enhance treatment options and better understand the disease, thereby addressing the urgent need for effective therapies in this rapidly evolving market.

Liver Cancer Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.82% over the forecast period (2024-2032)

Based on Drug Class segmentation, VEGF Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Liver Cancer Drug Market- Segmentation Analysis:

The Global Liver Cancer Drug Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: VEGF Inhibitors, PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors, and Immune Checkpoint Inhibitors. VEGF inhibitors rank highest in the Liver Cancer Drug Market due to their established efficacy in treating hepatocellular carcinoma. PD-1/PD-L1 inhibitors follow, offering promising immunotherapeutic options. Tyrosine kinase inhibitors (TKIs) are next, while immune checkpoint inhibitors are gaining traction for advanced cases.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy leads the Liver Cancer Drug Market due to its effectiveness and precision in treatment. Immunotherapy follows closely, providing innovative options for advanced liver cancer. Combination therapy ranks next, while chemotherapy remains a traditional approach with limited efficacy in advanced stages.

Liver Cancer Drug Market- Geographical Insights

North America dominates the Liver Cancer Drug Market, driven by advanced healthcare infrastructure and a high prevalence of liver cancer, particularly in the United States. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy involving lenvatinib and pembrolizumab, marking a significant advancement in treatment options for patients with advanced hepatocellular carcinoma (HCC). Additionally, the American Cancer Society reported that liver cancer incidence rates have been rising steadily, prompting increased funding for research initiatives aimed at better diagnostic tools and therapeutic options. In Europe, countries like Germany and France are witnessing a surge in clinical trials focusing on innovative drug combinations, reflecting a commitment to enhancing patient care. Asia-Pacific is emerging as a key region, with significant investments in liver cancer research due to the high prevalence of hepatitis-related liver cancer. Collaborations, such as the partnership between pharmaceutical companies and research institutions in Japan, aim to expedite the development of new therapies, highlighting a global effort to combat liver cancer effectively.

Liver Cancer Drug Market- Competitive Landscape:

The competitive landscape of the Liver Cancer Drug Market is predominantly led by North America, where major pharmaceutical companies like Bayer, Bristol-Myers Squibb, and Merck are actively advancing their portfolios. In 2023, Bayer announced the launch of a new formulation of sorafenib, aimed at improving patient adherence and outcomes in hepatocellular carcinoma (HCC) treatment. Meanwhile, Bristol-Myers Squibb's collaboration with the National Cancer Institute has accelerated the development of novel immunotherapies, significantly enhancing treatment options available to patients. In recent news, Merck's acquisition of a biotechnology firm specializing in liver cancer research has fortified its position in the market, allowing for an expanded pipeline of innovative therapies. Additionally, the European market is witnessing increased activity, with clinical trials underway for combination therapies that incorporate existing drugs with emerging agents, reflecting a growing trend towards personalized medicine. These developments highlight a dynamic competitive environment where collaboration, innovation, and strategic partnerships are essential for advancing treatment options and improving patient outcomes in the liver cancer landscape.

Recent Developments:

In August 2024, Bristol Myers Squibb's supplemental biologics license application for the first-line treatment of unresectable hepatocellular carcinoma was accepted by the FDA. This marks a significant step in advancing treatment options for patients with this type of liver cancer.

In February 2024, The FDA granted fast-track designation to BST02, a T-cell therapy for all liver cancer types, including hepatocellular carcinoma and cholangiocarcinoma. This innovative treatment utilizes tumor-infiltrating lymphocytes and is set for evaluation in a phase 1/2 clinical trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIVER CANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genentech, Inc. (Roche)
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Others

GLOBAL LIVER CANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

VEGF Inhibitors
PD-1/PD-L1 Inhibitors
Tyrosine Kinase Inhibitors (TKIs)
Immune Checkpoint Inhibitors

GLOBAL LIVER CANCER DRUG MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

Chemotherapy
Targeted Therapy
Immunotherapy
Combination Therapy

GLOBAL LIVER CANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous

GLOBAL LIVER CANCER DRUG MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Oncology Clinics
Research Institutes

GLOBAL LIVER CANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Liver Cancer Drug Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Liver Cancer Drug Market Snippet by Drug Class
- 2.1.2. Liver Cancer Drug Market Snippet by Therapy Type
- 2.1.3. Liver Cancer Drug Market Snippet by Route of Administration
- 2.1.4. Liver Cancer Drug Market Snippet by End-User
- 2.1.5. Liver Cancer Drug Market Snippet by Country
- 2.1.6. Liver Cancer Drug Market Snippet by Region
2.2. Competitive Insights

3. Liver Cancer Drug Key Market Trends

3.1. Liver Cancer Drug Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Liver Cancer Drug Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Liver Cancer Drug Market Opportunities
3.4. Liver Cancer Drug Market Future Trends

4. Liver Cancer Drug Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Liver Cancer Drug Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Liver Cancer Drug Market Landscape

6.1. Liver Cancer Drug Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Liver Cancer Drug Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. VEGF Inhibitors
- 7.1.3. PD-1/PD-L1 Inhibitors
- 7.1.4. Tyrosine Kinase Inhibitors (TKIs)
- 7.1.5. Immune Checkpoint Inhibitors

8. Liver Cancer Drug Market - By Therapy Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
- 8.1.2. Chemotherapy
- 8.1.3. Targeted Therapy
- 8.1.4. Immunotherapy
- 8.1.5. Combination Therapy

9. Liver Cancer Drug Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Intravenous

10. Liver Cancer Drug Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Oncology Clinics
- 10.1.4. Research Institutes

11. Liver Cancer Drug Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Liver Cancer Drug Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Liver Cancer Drug Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Liver Cancer Drug Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Liver Cancer Drug Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Liver Cancer Drug Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Liver Cancer Drug Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. Amgen Inc.
- 12.2.3. AstraZeneca PLC
- 12.2.4. Bayer AG
- 12.2.5. Bristol-Myers Squibb Company
- 12.2.6. Eisai Co., Ltd.
- 12.2.7. Eli Lilly and Company
- 12.2.8. F. Hoffmann-La Roche AG
- 12.2.9. Genentech, Inc. (Roche)
- 12.2.10. Gilead Sciences, Inc.
- 12.2.11. GlaxoSmithKline plc
- 12.2.12. Merck & Co., Inc.
- 12.2.13. Novartis AG
- 12.2.14. Pfizer Inc.
- 12.2.15. Sanofi S.A.
- 12.2.16. Takeda Pharmaceutical Company Limited
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us